Phaseline

Targets › PLK4

PLK4 (Serine/threonine-protein kinase PLK4): drug programs, companies and trials

1 program from 1 company in 5 trials: 4 Phase 2, 1 Phase 1; Oncology.

Serine/threonine-protein kinase that plays a central role in centriole duplication. Able to trigger procentriole formation on the surface of the parental centriole cylinder, leading to the recruitment of centriole biogenesis proteins such as SASS6, CPAP, CCP110, CEP135 and gamma-tubulin. (UniProt, O00444)

Open in Phaseline: the race on PLK4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Treadwell TherapeuticsCFI-400945
Serine/threonine-protein kinase PLK4 inhibitor
PLK4Phase 1Acute Myeloid Leukemia; Prostate Cancer; Breast Cancer–

Conditions

Breast Cancer (3) Acute Myeloid Leukemia (1) Prostate Cancer (1)

Modalities

small molecule (1)

Companies

Treadwell Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.